id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-271090-91lzr4tz	Edwards, Kathryn M.	Anticipating SARS-CoV-2 Vaccine Testing, Licensure, and Recommendations for Use	2020-06-19		.txt	text/plain	2694	142	47	Because of concerns raised about enhanced disease after wild virus infection in animal studies following vaccination against severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle East respiratory syndromecoronavirus (MERS-CoV) (9, 10), experts have met and proposed immunologic criteria to be evaluated in animals and humans to detect and consequently reduce the risk of enhanced disease (11) . Some of the Phase 1 studies evaluating SARS-CoV-2 vaccines have also included individuals >65 years of age to assess safety and immunogenicity in this population, which is at greater risk for severe COVID-19 disease. With SARS-CoV-2 vaccines, Phase 2 studies are planned to expand the safety profile and to assess immune responses in larger numbers of subjects. The Phase 3 efficacy trials planned for SARS-CoV-2 vaccines in the United States are expected to enroll 20,000 to 30,000 individuals, the numbers projected to be necessary to determine whether the vaccines will prevent significant disease over a period of 6 months follow-up.	./cache/cord-271090-91lzr4tz.txt	./txt/cord-271090-91lzr4tz.txt